These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 6316420

  • 1. The effects of continuous infusions of prostacyclin-Na (epoprostenol-sodium) on platelet counts, ADP-induced aggregation, and cyclic AMP levels in normal volunteers.
    Reele SB, Miller OV, Spillers C, Gorman RR.
    Prostaglandins; 1983 Aug; 26(2):287-302. PubMed ID: 6316420
    [Abstract] [Full Text] [Related]

  • 2. A chemically stable analogue, 9 beta-methyl carbacyclin, with similar effects to epoprostenol (prostacyclin, PGI2) in man.
    O'Grady J, Hedges A, Whittle BJ, Al-Sinawi LA, Mekki QA, Burke C, Moody SG, Moti MJ, Hassan S.
    Br J Clin Pharmacol; 1984 Dec; 18(6):921-33. PubMed ID: 6085004
    [Abstract] [Full Text] [Related]

  • 3. Intravenous infusion of prostacyclin sodium in man: clinical effects and influence on platelet adenosine diphosphate sensitivity and adenosine 3':5'-cyclic monophosphate levels.
    Data JL, Molony BA, Meinzinger MM, Gorman RR.
    Circulation; 1981 Jul; 64(1):4-12. PubMed ID: 6263515
    [Abstract] [Full Text] [Related]

  • 4. Sub-aggregatory doses of catecholamines prevent prostacyclin-induced inhibition of platelet aggregation.
    Buttrick PM, Forscher CA, Sussman II, Mueller HS.
    Am Heart J; 1985 Jun; 109(6):1258-63. PubMed ID: 2988323
    [Abstract] [Full Text] [Related]

  • 5. Refractoriness of platelets to prostaglandins after infusion in rabbits.
    Bertelé V, Stemerman M, Schafer A, Adelman B, Smith M, Fuhro R, Salzman E.
    J Lab Clin Med; 1985 Nov; 106(5):551-61. PubMed ID: 2997353
    [Abstract] [Full Text] [Related]

  • 6. Intracellular levels of cyclic AMP and cyclic GMP differentially modify platelet aggregate size in human platelets activated with epinephrine or ADP.
    Qi R, Ozaki Y, Satoh K, Yang LB, Asazuma N, Yatomi Y, Kume S.
    J Cardiovasc Pharmacol; 1996 Aug; 28(2):215-22. PubMed ID: 8856476
    [Abstract] [Full Text] [Related]

  • 7. Effect of heparin on platelet aggregation inhibited by PGI2, trifluoperazine and verapamil.
    Weber DR, Nichols WK, Mohammad SF.
    Thromb Res; 1986 May 15; 42(4):477-87. PubMed ID: 3012821
    [Abstract] [Full Text] [Related]

  • 8. Regulation of human platelet activation--analysis of cyclooxygenase and cyclic AMP-dependent pathways.
    Krishnamurthi S, Westwick J, Kakkar VV.
    Biochem Pharmacol; 1984 Oct 01; 33(19):3025-35. PubMed ID: 6091666
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Platelet function studies during and after infusions of ZK 36374, a stable prostacyclin analogue, to healthy volunteers.
    Yardumian DA, Mackie IJ, Brennan EC, Bull H, Machin SJ.
    Haemostasis; 1986 Oct 01; 16(1):20-6. PubMed ID: 2422095
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Role of cyclic AMP in the inhibition of human platelet aggregation by quercetin, a flavonoid that potentiates the effect of prostacyclin.
    Beretz A, Stierle A, Anton R, Cazenave JP.
    Biochem Pharmacol; 1982 Nov 15; 31(22):3597-600. PubMed ID: 6295405
    [Abstract] [Full Text] [Related]

  • 13. Platelet prostacyclin binding in smokers.
    Jaschonek K, Weisenberger H, Tidow S, Daiss W, Renn W, Ostendorf P.
    J Lab Clin Med; 1986 Aug 15; 108(2):88-95. PubMed ID: 3016128
    [Abstract] [Full Text] [Related]

  • 14. Increased platelet activity after termination of prostacyclin infusion into man.
    Dembinska-Kiec A, Zmuda A, Grodzinska L, Bieron K, Basista M, Kedzior A, Kostka-Trabka E, Telesz E, Zelazny T.
    Prostaglandins; 1981 May 15; 21(5):827-32. PubMed ID: 6803307
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Tolerance and pharmacology of ciprostene, a stable epoprostenol (prostacyclin) analogue in humans.
    Linet OI, Nishizawa EE, Schaub RG, VanderLugt JT, Greenwald CA.
    J Clin Pharmacol; 1986 Feb 15; 26(2):131-40. PubMed ID: 3005377
    [Abstract] [Full Text] [Related]

  • 17. Single-blind study of epoprostenol and 6-keto-prostaglandin E1 in man: effects of platelet aggregation and plasma renin.
    Miyamori I, Morise T, Yasuhara S, Takeda Y, Koshida H, Takeda R.
    Br J Clin Pharmacol; 1985 Dec 15; 20(6):681-3. PubMed ID: 3912001
    [Abstract] [Full Text] [Related]

  • 18. The cardiovascular and platelet effects of epoprostenol (prostacyclin, PGI2) are unaffected by beta-adrenoceptor blockade in man.
    Hassan S, Pickles H, Fish A, Burke C, Warrington S, O'Grady J.
    Br J Clin Pharmacol; 1982 Sep 15; 14(3):369-77. PubMed ID: 6127095
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.